Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 12;6(1):e711. doi: 10.1038/tp.2015.191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

The increased levels of MeCP2 binding to Gad1, Reln and Bdnf-ix promoter regions in the frontal cortex of PRS mice are reduced by treatment with clozapine but not haloperidol. The dose and schedule of drug treatments are described in Figure 2. The data are expressed as mean±s.e.m. One-way ANOVA for MeCP2 binding to Reln (F_5,18=4.96, P=0.03), Gad1 (F_5,18=6.07, P=0.009), Bdnf-ix (F_5,18=4.80, P=0.028). *P<0.05 when vehicle-treated PRS samples are compared with PRS clozapine-treated samples or to vehicle-treated NS samples. ^#P<0.05 when haloperidol-treated PRS samples are compared with PRS clozapine-treated samples or with treated and untreated NS samples. Student–Newman–Keuls multiple comparisons. ANOVA, analysis of variance; BDNF, brain-derived neurotrophic factor.